BioSante Presents Positive Data On Inhaled Insulin.Business Editors/Health/Medical Writers BIOWIRE2K LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Dec. 8, 2003 BioSante Pharmaceuticals, Inc. (Amex:BPA BPA British Paediatric Association. ) today announced that it presented data on its new nanoparticulate-based technology for the delivery of insulin at the Pharmaceutical Education Associates symposium on Inhalation Drug Delivery in Princeton, New Jersey
Princeton, New Jersey is located in Mercer County, New Jersey, United States. Princeton University has been sited in the town since 1756. , last week. "Among efficacy studies that evaluate various inhalable insulin Inhalable insulin is a new (as of mid-2006) method of delivering insulin, a drug used in the treatment of diabetes, to the body. It is the first new treatment option of insulin since the discovery of insulin in 1921[1], traditionally administered by subcutaneous injection. formulations and are relevant for comparison, our formulation demonstrated the highest bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. using the smallest dose," said Dr. Tulin Morcol, associate director of drug delivery and related technologies for BioSante. The company is also developing promising new systems for the administration of insulin in oral tablet or capsule form, as well as via long-acting injection. The presentation summarized positive results from a series of preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. of the company's BioAir(TM) calcium phosphate calcium phosphate n. 1. A colorless deliquescent powder, Ca(H2PO4)2, used in baking powders, as a plant food, as a plastic stabilizer, and in glass. 2. nanoparticulate (CAP) delivery system for inhalable insulin. The studies showed the BioSante formulation significantly increased the systemic residence time and duration of action of the insulin, increasing the amount of insulin that became available through the bloodstream (bioavailability) 1.8 times over that of injected insulin. "We are pleased with the progress we have made toward the development of important new delivery methods for insulin and other therapies," said Stephen M. Simes, president and chief executive officer of BioSante. "The development of an inhalable insulin would represent an easy, pain-free alternative to insulin injections, allowing diabetics to live more normal, comfortable lives." About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy Hormone therapy Treating cancers by changing the hormone balance of the body, instead of by using cell-killing drugs. Mentioned in: Breast Cancer, Thyroid Cancer hormone therapy products to treat both men and women. The company is also developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems. Additional information is available online at www.biosantepharma.com. This news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, adverse reports from others about products similar to ours, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed on pages 17 to 23 of BioSante's Form 10-KSB, which discussion also is incorporated herein by reference. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion